Roche’s Plan Is Working: Rituxan Bested By Follow-On GA101 In Head-To-Head Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Obinutuzumab (GA101) provided a survival advantage over the venerable Rituxan in new CLL patients, marking another milestone for Roche/Genentech in the replace-and-extend strategy for its anti-CD20 franchise.
You may also be interested in...
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.